China’s CMAB Biopharma captures $34M in series B funding to upgrade facilities

Suzhou, China
The company said it will use the funds to upgrade its plant in the Suzhou BioBay Park in China. (Christian Gänshirt/CC BY-SA 4.0)

CMAB Biopharma, a China-based CDMO, snagged $34 million in series B financing the company said will be used to upgrade and expand its manufacturing plant.

The company, which specializes in the development and manufacturing of biologics products, said it will use the funds to upgrade its plant in the Suzhou BioBay Park in China. 

The funding round was led by CD Capital, with joint participation by C-Bridge Capital, Cormorant, Qianhai FoF Fund and Tigermed.

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

“We aim to bring our client expertise and knowledge to efficiently advance products from concept into the clinic,” Qibin Liang, CMAB’s president, said in a statement. “This financing furthers our vision to become a fully integrated CDMO platform providing clinical and commercial production services to the Chinese domestic and the international biologics markets.”

The company said its manufacturing facility will be able to generate preclinical and early-stage clinical (phase 1/2) products using manufacturing that follows global GMP standards.


Suggested Articles

Gilead Sciences will donate 1.5 million doses of COVID-19 hopeful remdesivir as its manufacturing of the drug hits light speed.

Sanofi, a hydroxychloroquine maker, is producing as much as it can amid the pandemic, but some workers are having to exit the line manufacturing line.

The White House asked the FDA to clear Avigan for COVID-19. FTC delays forced Aurobindo and Novartis to end generics deal. China's API output dropped.